I think Hims & Hers Health has achieved "escape velocity", with a 95%+ increase year-over-year in Q4 2024 and expected 56%-63% growth in 2025, net of GLP-1 issues. The market overreacted to HIMS ...

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded versions of Ozempic and Wegovy. This approach is in response to ...

One doctor is losing her lunch over a bizarre ad in the window of a new pizza-bagel joint in Midtown that encourages people to take a popular weight-loss drug after wolfing down a meal there.

Hims & Hers Health, Inc. (HIMS) shares rallied 5.7% in the last trading session to close at $34.75. This move can be attributable to notable volume with a higher number of shares being traded than ...

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an all-time high by late February – only to plunge by half in ...

In this article, we are going to take a look at where Hims & Hers Health Inc (NYSE:HIMS) stands against other defensive stocks that are surging in 2025. Defensive stocks are surging as investors ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Hims & Hers has risen 70% since November 2024, outperforming the S&P 500, despite recent regulatory challenges impacting its compounded semaglutide product. Its diversified portfolio in men's and ...

It has been about a month since the last earnings report for Hims & Hers Health, Inc. (HIMS). Shares have lost about 7.1% in that time frame, underperforming the S&P 500. Will the recent negative ...